Clinical Trials · NCT05813249

Semaglutide in Nonalcoholic Fatty Liver Disease

Name: Semaglutide in Nonalcoholic Fatty Liver Disease
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Semaglutide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Zagazig University
Enrollment: 180
Start date: Feb 2023
Locations: 1 site, Egypt
Primary endpoint: NAFLD regression

View Semaglutide compound reference